TMDX
TransMedics Group, Inc.
$93.52
-0.08
(-0.08%)
Mkt Cap
3.23B
Volume
196,409
52W Range
60.105-156
Sector
Healthcare
Beta
1.88
EPS (TTM)
4.42 USD
P/E Ratio
21.15
Revenue (TTM)
668.47M USD
Rev Growth (5Y)
+88.2%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$148.38
Undervalued
moderate signal
37.0% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 605.49M | 441.54M | 241.62M | 93.46M | 30.26M | 25.64M | 23.60M | 13.02M | 7.68M | 6.21M |
| Net Income | 190.29M | 35.46M | (25.03M) | (36.23M) | (44.22M) | (28.75M) | (33.55M) | (23.76M) | (20.82M) | (24.07M) |
| EPS | 5.60 | 1.07 | -0.77 | -1.23 | -1.60 | -1.16 | -2.36 | -1.23 | -1.44 | -1.66 |
| Free Cash Flow | 133.59M | (80.94M) | (192.09M) | (57.72M) | (32.38M) | (30.72M) | (32.45M) | (26.40M) | (23.36M) | (25.59M) |
| FCF / Share | 3.93 | -2.44 | -5.91 | -1.95 | -1.17 | -1.24 | -2.28 | -1.37 | -1.61 | -1.77 |
| Operating CF | 192.84M | 48.80M | (13.03M) | (45.82M) | (28.86M) | (30.27M) | (32.29M) | (25.98M) | (23.10M) | (24.11M) |
| Total Assets | 1.07B | 804.08M | 706.05M | 277.15M | 134.89M | 152.03M | 105.30M | 42.16M | 37.00M | 58.10M |
| Total Debt | 469.69M | 518.29M | 515.95M | 67.56M | 43.80M | 34.66M | 34.15M | 33.67M | 8.65M | 8.41M |
| Cash & Equiv | 488.37M | 336.65M | 394.81M | 201.18M | 25.58M | 24.58M | 20.09M | 20.24M | 11.94M | 9.84M |
| Book Value | 473.10M | 228.60M | 137.20M | 187.38M | 67.85M | 103.89M | 54.65M | (4.83M) | (168.72M) | 38.79M |
| Return on Equity | 0.40 | 0.16 | -0.18 | -0.19 | -0.65 | -0.28 | -0.61 | N/A | N/A | -0.62 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 189.95M | 173.93M | 160.76M | 143.82M | 157.37M | 143.54M | 121.62M | 108.76M | 114.31M | 96.85M | 81.17M | 66.43M |
| Net Income | 14.68M | 7.32M | 105.38M | 24.32M | 34.91M | 25.68M | 6.86M | 4.22M | 12.19M | 12.20M | 4.03M | (25.42M) |
| EPS | 0.42 | 0.21 | 3.08 | 0.71 | 1.03 | 0.76 | 0.20 | 0.13 | 0.37 | 0.37 | 0.12 | -0.78 |
| Free Cash Flow | 10.22M | (12.12M) | 19.00M | 61.95M | 82.53M | (29.89M) | 6.06M | (41.35M) | 1.96M | (47.61M) | (33.51M) | (114.59M) |
| FCF / Share | 0.30 | -0.35 | 0.56 | 1.82 | 2.43 | -0.89 | 0.18 | -1.24 | 0.06 | -1.45 | -1.03 | -3.51 |
| Operating CF | 17.31M | 24.53M | 34.51M | 69.57M | 91.61M | (2.85M) | 19.66M | 6.86M | 25.72M | (3.44M) | 8.30M | (6.87M) |
| Total Assets | 1.46B | 1.43B | 1.07B | 946.03M | 890.52M | 837.53M | 804.08M | 785.57M | 758.58M | 723.83M | 706.05M | 689.23M |
| Total Debt | 867.72M | 863.41M | 469.69M | 519.35M | 518.82M | 518.41M | 518.29M | 518.15M | 516.49M | 516.22M | 515.95M | 515.65M |
| Cash & Equiv | 472.68M | 461.74M | 488.37M | 466.17M | 400.57M | 310.14M | 336.65M | 330.09M | 362.75M | 350.22M | 394.81M | 427.11M |
| Book Value | 518.05M | 494.01M | 473.10M | 355.20M | 318.10M | 266.31M | 228.60M | 209.92M | 189.89M | 159.47M | 137.20M | 126.46M |
| Return on Equity | 0.03 | 0.01 | 0.22 | 0.07 | 0.11 | 0.10 | 0.03 | 0.02 | 0.06 | 0.08 | 0.03 | -0.20 |
TMDX News
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
30,456 Shares in TransMedics Group, Inc. $TMDX Acquired by Emerald Investment Advisers LLC
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Breakfast News: Week in Review
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
Breakfast News: Alphabet Goes Shopping for Data
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX